Literature DB >> 2037383

Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

D M Lyerly1, E F Bostwick, S B Binion, T D Wilkins.   

Abstract

Gestating Holstein cows were vaccinated with Clostridium difficile toxoid prepared from the culture filtrate of a strain that produces high levels of toxins A and B and other antigens. A bovine immunoglobulin G (IgG) concentrate was prepared from colostrum collected at parturition. The results of our studies showed that hamsters treated prophylactically with the hyperimmune bovine IgG concentrate were protected against C. difficile disease. These results suggest that orally administered hyperimmune bovine IgG specific for C. difficile culture filtrate may be useful in prophylaxis against C. difficile disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037383      PMCID: PMC257992          DOI: 10.1128/iai.59.6.2215-2218.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Nucleotide sequence of Clostridium difficile toxin B gene.

Authors:  L A Barroso; S Z Wang; C J Phelps; J L Johnson; T D Wilkins
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

2.  Molecular characterization of the Clostridium difficile toxin A gene.

Authors:  C H Dove; S Z Wang; S B Price; C J Phelps; D M Lyerly; T D Wilkins; J L Johnson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

Review 3.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

4.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  Production of Clostridium difficile antitoxin.

Authors:  M Ehrich; R L Van Tassell; J M Libby; T D Wilkins
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

6.  Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice.

Authors:  R Fayer; A Guidry; B L Blagburn
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

7.  Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study.

Authors:  C M Surawicz; G W Elmer; P Speelman; L V McFarland; J Chinn; G van Belle
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

8.  Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins.

Authors:  C Mietens; H Keinhorst; H Hilpert; H Gerber; H Amster; J J Pahud
Journal:  Eur J Pediatr       Date:  1979       Impact factor: 3.183

9.  Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

Authors:  M B Kimmey; G W Elmer; C M Surawicz; L V McFarland
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

10.  Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis.

Authors:  K H Wilson; J Silva; F R Fekety
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

View more
  46 in total

1.  Veterinary nutraceutical medicine.

Authors:  C Taillon; A Andreasen
Journal:  Can Vet J       Date:  2000-03       Impact factor: 1.008

2.  Comments regarding the claimed effectiveness of bovine colostrum.

Authors:  S Weese
Journal:  Can Vet J       Date:  2000-06       Impact factor: 1.008

Review 3.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 4.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

5.  Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Authors:  April Roberts; Joanna McGlashan; Ibrahim Al-Abdulla; Roger Ling; Harriet Denton; Steve Green; Ruth Coxon; John Landon; Clifford Shone
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 6.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

8.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

9.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

Authors:  J F Torres; D M Lyerly; J E Hill; T P Monath
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.